Publication:
Drug–drug interactions in adjuvant and neoadjuvant breast cancer therapy

Simple item page
dc.contributor.authorMiguel Almanchel Rivadeneyra
dc.contributor.authorAina Tomás Luiz
dc.contributor.authorAlonso Romero, José Luis
dc.contributor.authorDíaz Carrasco, María Sacramento
dc.contributor.departmentFarmacología
dc.contributor.otherFacultades de la UMU::Facultad de Medicina
dc.date.accessioned2026-03-25T12:46:57Z
dc.date.available2026-03-25T12:46:57Z
dc.date.issued2026
dc.description.abstractObjective To determine the prevalence, severity and characteristics of potential drug–drug interactions (DDIs) in a homogeneous cohort of patients with early-stage breast cancer receiving adjuvant or neoadjuvant chemotherapy. Methods We performed a retrospective observational study of patients treated with systemic chemotherapy at a tertiary hospital. All medications prescribed during chemotherapy were recorded. Potential DDIs were identified using the Lexicomp database and classified by risk level, clinical severity, quality of evidence and mechanism of action. Associations between patient-related factors and DDIs were analysed. Results A total of 273 patients were included (median age 52 years) and 56% had at least one comorbidity. Overall, 2842 drugs were prescribed (median 10 per patient), resulting in 2287 potential DDIs. All patients presented at least one DDI; 89% had at least one type D interaction and 14.6% at least one type X interaction. Most DDIs were classified as type C (75.3%), followed by type D (21.7%) and type X (3.0%). The total number of DDIs was significantly associated with age, comorbidity burden and number of prescribed drugs. Conclusions Potential DDIs are highly prevalent in patients with early-stage breast cancer receiving chemotherapy, with a substantial proportion involving clinically significant or contraindicated combinations. Polypharmacy, age and comorbidities are key risk factors, highlighting the importance of systematic medication review and interdisciplinary collaboration to improve treatment safety.
dc.formatapplication/pdf
dc.format.extent9
dc.identifier.citationAlmanchel-Rivadeneyra, M., Romero, J. L. A., Tomás-Luiz, A., & Carrasco, M. S. D. (2026). Drug–drug interactions in adjuvant and neoadjuvant breast cancer therapy. European Journal of Hospital Pharmacy.
dc.identifier.doihttps://doi.org/10.1136/ejhpharm-2025-004761
dc.identifier.urihttp://hdl.handle.net/10201/222921
dc.languageeng
dc.publisherBMJ journals
dc.relationSin financiación externa a la Universidad
dc.relation.publisherversionhttps://ejhp.bmj.com/content/early/2026/01/05/ejhpharm-2025-004761
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccess
dc.subject.odsNo relacionado con ningún objetivo de desarrollo sostenible
dc.titleDrug–drug interactions in adjuvant and neoadjuvant breast cancer therapy
dc.typeinfo:eu-repo/semantics/article
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dspace.entity.typePublicationes
relation.isAuthorOfPublication79c9c691-9c36-4057-91b8-cf928d76847b
relation.isAuthorOfPublicationb4864f00-73c6-47e3-8751-eb0c33e80d00
relation.isAuthorOfPublication.latestForDiscovery79c9c691-9c36-4057-91b8-cf928d76847b
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ejhpharm-2025-004761.full (1).pdf
Size:
343.6 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos